Summary of efficacy outcomes from selected trials evaluating thalidomide-based regimens in elderly patients with NDMM
| Study . | Median follow-up, mo . | Treatment . | n . | CR + PR, % . | CR, % . | PFS, mo . | OS, mo . |
|---|---|---|---|---|---|---|---|
| IFM 99-0612 | 51.5 | MPT | 124 | 76 | 13 | 27.5 | 51.6 |
| MP | 193 | 35 | 2 | 17.8 | 33.2 | ||
| GIMEMA13 | 38.1 | MPT | 159 | 76 | 16 | 21.8 | 45.0 |
| MP | 160 | 48 | 4 | 14.5 | 47.6 | ||
| Nordic15 | 42 | MPT | 182 | 57 | 13 | 15.0 | 29.0 |
| MP | 175 | 40 | 4 | 14.0 | 32.0 | ||
| HOVON16 | 39 | MPT | 165 | 66 | NA | 13* | 40 |
| MP | 168 | 45 | NA | 9* | 31 | ||
| IFM 01-0111 | 47.5 | MPT | 113 | 62 | 7 | 24.1 | 44.0 |
| MP | 116 | 31 | 1 | 18.5 | 29.1 | ||
| Ludwig et al10 | 28.1 | TD | 145 | 68 | 2 | 16.7 | 41.5 |
| MP | 143 | 50 | 2 | 20.7 | 49.4 | ||
| Morgan et al (current study) | 44 | CTDa | 426 | 64 | 13 | 13.0 | 33.2 |
| MP | 423 | 33 | 2 | 12.4 | 30.6 |
| Study . | Median follow-up, mo . | Treatment . | n . | CR + PR, % . | CR, % . | PFS, mo . | OS, mo . |
|---|---|---|---|---|---|---|---|
| IFM 99-0612 | 51.5 | MPT | 124 | 76 | 13 | 27.5 | 51.6 |
| MP | 193 | 35 | 2 | 17.8 | 33.2 | ||
| GIMEMA13 | 38.1 | MPT | 159 | 76 | 16 | 21.8 | 45.0 |
| MP | 160 | 48 | 4 | 14.5 | 47.6 | ||
| Nordic15 | 42 | MPT | 182 | 57 | 13 | 15.0 | 29.0 |
| MP | 175 | 40 | 4 | 14.0 | 32.0 | ||
| HOVON16 | 39 | MPT | 165 | 66 | NA | 13* | 40 |
| MP | 168 | 45 | NA | 9* | 31 | ||
| IFM 01-0111 | 47.5 | MPT | 113 | 62 | 7 | 24.1 | 44.0 |
| MP | 116 | 31 | 1 | 18.5 | 29.1 | ||
| Ludwig et al10 | 28.1 | TD | 145 | 68 | 2 | 16.7 | 41.5 |
| MP | 143 | 50 | 2 | 20.7 | 49.4 | ||
| Morgan et al (current study) | 44 | CTDa | 426 | 64 | 13 | 13.0 | 33.2 |
| MP | 423 | 33 | 2 | 12.4 | 30.6 |
NA indicates not applicable.
Values are event-free survival, not PFS.